CD4 and COVID-19: COVID-19 vaccination with both BNT162b2 or ChAdOx1 induces robust CD4+ and CD8+ tetramer+ T cells toward immunodominant spike-specific epitopes in healthy participants (42, 44) and high-risk groups, including hematology patients, individuals with autoimmunity, and First Nations people (41, 52, 53).